|
Pulmonary and Critical Care Medicine 2024 - LIVE STREAMING
Comprehensive Updates for State-of-the-Art Evaluation, Diagnosis, and Treatment
This comprehensive live streaming online course, which is among the highest-rated Harvard Medical School CME courses, provides education and updates to optimize your care of patients with:
• Sepsis
• ARDS
• Sarcoidosis
• IPF
• Bronchiectasis
• Cystic fibrosis
• Lung nodules
• Lung cancer
• GERD
• Pleural disease
• Pneumonia
• Tuberculosis
• Thromboembolism
• Chronic cou... |
|
WEBINAR: Data Gaps in Aquatic Pharmacology: Identifying Challenges and Needs
Administering medications to animals living in an aquatic environment poses unique challenges compared to their terrestrial counterparts. This talk will review the basic considerations when choosing and administering medication to fish and sharks and identify areas where we lack scientific data to support our medication choices. Medication behavior and its relationship to filtration and other environmental factors such as water pH, temperature, and alkalinity will also be covered.
This web... |
|
Reducing Risks in Asthma: Mucus Plugs and Airway Obstruction
Target Audience
The educational design of this activity addresses the needs of pulmonology and clinical immunology clinicians who manage patients with severe asthma who are at risk for mucus plugs.
Program Overview
This Point-of-Care 201 program has been designed to educate and promote critical thinking through a discussion-based format that is accompanied by 3-dimensional animation. Expert faculty examine various sides of key clinical issues in asthma"including exploration of the pa... |
|
Raising the Bar in ATTR Amyloidosis A Training Set on Diagnosis and Treatment
There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite this progress, treatment options remain limited, underscoring the need to continue to expand the tre... |